60208-07-3

Usage

Uses

Used in Pharmaceutical Industry:
2-bromo-2-4-dibromoacetophenone is used as a reagent in the synthesis of pharmaceuticals for its ability to facilitate the production of various medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical industry, 2-bromo-2-4-dibromoacetophenone is used as a reagent in the development of agrochemicals, contributing to the creation of products that enhance crop protection and yield.
Used in Dye Industry:
2-bromo-2-4-dibromoacetophenone is utilized as a reagent in the production of dyes, playing a role in the synthesis of colorants for various applications.
Used as an Intermediate in Chemical Manufacture:
2-bromo-2-4-dibromoacetophenone serves as an intermediate in the manufacture of other chemicals, indicating its importance in the synthesis of a wide range of products.
Used in Medicine:
2-bromo-2-4-dibromoacetophenone has potential applications in medicine, likely due to its antimicrobial properties, which can be harnessed in the development of treatments for various conditions.
Used in Agriculture:
Its potential use in agriculture is attributed to its antimicrobial properties, which can be beneficial in creating solutions for crop protection and enhancement of yield.
Used in Materials Science:
2-bromo-2-4-dibromoacetophenone's reactivity and properties make it a candidate for use in materials science, possibly for developing new materials with specific characteristics.
Overall, 2-bromo-2-4-dibromoacetophenone is a versatile chemical compound with applications spanning across several industries, including pharmaceuticals, agrochemicals, dyes, chemical manufacturing, medicine, agriculture, and materials science.

Upstream product

• 2234-16-4 1-(2,4-dichlorophenyl)ethan-1-one 
• 33243-33-3 2,4-dibromoacetophenone 

Downstream Products

• 126961-68-0 4-Amino-1-[2-(2,4-dibromo-phenyl)-2-oxo-ethyl]-4H-[1,2,4]triazol-1-ium; bromide 
• 98165-40-3 1-(2,4-Dibromo-phenyl)-2-[1,2,4]triazol-1-yl-ethanone 
• 126961-74-8 1-(2,4-Dibromo-phenyl)-2-[1,2,4]triazol-1-yl-ethane-1,2-dione 2-oxime 
• 1246766-45-9 C₁₈H₈Br₂F₆N₂O₂S 

Relevant academic research and scientific papers

Novel arylimino thiazole compound, preparation method and uses thereof

The present invention relates to a compound with antibacterial synergy activity, a preparation and uses thereof, particularly to a novel arylimino thiazole compound, a preparation method and uses thereof, and specifically discloses a class of compounds represented by a formula (I) or optical isomers, cis-trans isomers or pharmaceutically acceptable salts thereof, a preparation method and uses thereof. The invention further discloses a pharmaceutical composition containing the compound. The compound of the present invention can effectively enhance the antibacterial activity of antibiotics, andcan be used for treating antibiotic-resistant bacteria. The formula (I) is defined in the specification.

Antibacterial synergist, preparation method and uses thereof

The present invention relates to an antibacterial synergist, a preparation method and uses thereof, and specifically discloses a compound represented by a formula (I) and having antibacterial synergyactivity, or an optical isomer, a cis-trans isomer or a pharmaceutically acceptable salt thereof, and a preparation method thereof. The present invention further discloses a medical composition containing the compound, and uses thereof. According to the present invention, the compound can effectively enhance the antibacterial activity of polymyxin B against Acinetobacter baumannii and Klebsiella pneumoniae, and can be used for the antibacterial treatment of pathogenic bacteria insensitive to polymyxin or having low bacterial inhibition activity. The formula (I) is defined in the specification.

Substituted pyrimidines

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Process for producing optically active carbinols

The present invention relates to a process for producing optically active halomethyl phenyl carbinols of the formula (1), comprising reducing halomethyl phenyl ketones of the formula (2) using an asymmetric reducing agent obtained from boranes and optically active α-phenyl-substituted-β-amino alcohols of the formula (3) or optically active α-non-substituted-β-amino alcohols of the formula (4). The present invention further relates to a process for producing optically active carbinols, comprising reacting a prochiral keytone with an asymmetric reducing agent obtained from optically active β-amino alcohols of the formula (5), a metal boron hydride and Lewis acid or lower dialkyl sulfuric acid. All of the formulas (1) to (5) are the same as shown in the specification.